Clearbridge Investments LLC Sells 18,517 Shares of Medtronic PLC $MDT

Clearbridge Investments LLC cut its stake in shares of Medtronic PLC (NYSE:MDT) by 1.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,126,720 shares of the medical technology company’s stock after selling 18,517 shares during the quarter. Clearbridge Investments LLC’s holdings in Medtronic were worth $108,233,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Curbstone Financial Management Corp increased its stake in shares of Medtronic by 1.8% in the fourth quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company’s stock valued at $537,000 after buying an additional 100 shares in the last quarter. New England Capital Financial Advisors LLC lifted its position in Medtronic by 7.8% during the 4th quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company’s stock worth $135,000 after buying an additional 101 shares in the last quarter. Ipsen Advisor Group LLC lifted its position in Medtronic by 1.7% during the 4th quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock worth $572,000 after buying an additional 101 shares in the last quarter. Baker Tilly Wealth Management LLC grew its holdings in Medtronic by 3.3% during the 4th quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company’s stock worth $309,000 after acquiring an additional 102 shares during the last quarter. Finally, Maseco LLP increased its position in Medtronic by 32.1% in the 4th quarter. Maseco LLP now owns 444 shares of the medical technology company’s stock valued at $43,000 after acquiring an additional 108 shares in the last quarter. 82.06% of the stock is owned by institutional investors.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic won FDA clearance for its Nellcor pulse oximetry system with the Nell-EQ intelligent processor, a regulatory win that could expand adoption and support future medical-device sales. Medtronic wins FDA clearance for Nellcor pulse oximetry system with intelligent processor
• Positive Sentiment: Medtronic is also drawing favorable coverage around its recent earnings and revenue performance, with commentary calling it a potential value opportunity in healthcare after stronger-than-expected results. Why Medtronic Stock May Have Just Become the Best Buy in the Entire Healthcare Sector
• Positive Sentiment: Further upbeat articles frame Medtronic as a “dividend aristocrat” and suggest the shares may still be undervalued, reinforcing the idea that the stock could have room to run if execution stays solid. Medtronic: A Dividend Aristocrat At A Steal Now
• Positive Sentiment: Medtronic’s planned $650 million acquisition of SPR Therapeutics is being viewed as a strategic move to strengthen its pain-intervention business and broaden care options for chronic pain patients. Medtronic plc (MDT) Acquires SPR Therapeutics to Enhance Pain Intervention Prospects
• Neutral Sentiment: Some recent coverage is focused more on valuation and whether the stock is mispriced after its rebound, which may influence investor sentiment but does not represent a direct operational catalyst. Is It Time To Reassess Medtronic (MDT) After Its Recent Share Price Rebound?
• Neutral Sentiment: Broader healthcare roundup articles also mention Medtronic, but they appear to be more context than a specific new catalyst for the shares. Notable healthcare headlines for the week: UnitedHealth, Medtronic, and Eli Lilly in focus

Medtronic Price Performance

Shares of MDT stock opened at $80.65 on Tuesday. The stock has a 50-day moving average price of $81.31 and a 200 day moving average price of $91.87. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The firm has a market cap of $103.54 billion, a price-to-earnings ratio of 21.62, a PEG ratio of 1.99 and a beta of 0.58. Medtronic PLC has a 12 month low of $73.31 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. The firm had revenue of $9.81 billion during the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.20%.The company’s revenue was up 9.9% on a year-over-year basis. During the same period last year, the company earned $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Research analysts expect that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Investors of record on Friday, June 26th will be given a $0.72 dividend. The ex-dividend date is Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a yield of 3.6%. Medtronic’s dividend payout ratio is 76.14%.

Wall Street Analysts Forecast Growth

MDT has been the subject of several research reports. Citigroup lowered their price objective on shares of Medtronic from $117.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. Sanford C. Bernstein lowered their price objective on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating for the company in a research report on Thursday. Wells Fargo & Company lowered their price objective on shares of Medtronic from $114.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday, June 4th. JPMorgan Chase & Co. lowered their price objective on shares of Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a research report on Thursday, June 4th. Finally, Argus lowered their price objective on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Seventeen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to data from MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and an average price target of $99.00.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).